In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy

J Nucl Med. 2020 Sep;61(9):1337-1340. doi: 10.2967/jnumed.119.237818. Epub 2020 Jan 31.

Abstract

Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo in humans is crucial for personalized treatment management and understanding of treatment effects. Such an investigation requires input data on the in vivo stability of the radiopharmaceuticals in blood and plasma. The work presented here is devoted to the investigation of the in vivo stability of 177Lu-DOTATATE in humans affected by neuroendocrine tumors. Methods: Blood samples of 6 patients undergoing 177Lu-DOTATATE were taken at 0.5, 4, 24, and 96 h after injection. Analysis of metabolic stability was performed using high-performance liquid chromatography. Results: A fast metabolism of the radiopharmaceutical was observed, with the fraction of intact 177Lu-DOTATATE in plasma decreasing rapidly to 23% ± 5% (mean ± SD) at 24 h and 1.7% ±0. 9% at 96 h after injection. Conclusion: The in vivo stability of 177Lu-DOTATATE is much lower than previously assumed, with the major part of radioactivity in plasma consisting of 177Lu-labeled metabolites already at 24 h after injection.

Keywords: 177Lu-DOTATATE; Lutathera; dosimetry; neuroendocrine; radionuclide therapy; radiopharmaceuticals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Stability
  • Humans
  • Neuroendocrine Tumors / blood
  • Neuroendocrine Tumors / metabolism*
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / blood
  • Octreotide / metabolism
  • Octreotide / therapeutic use
  • Organometallic Compounds / blood
  • Organometallic Compounds / metabolism*
  • Organometallic Compounds / therapeutic use*
  • Receptors, Peptide / metabolism*

Substances

  • Organometallic Compounds
  • Receptors, Peptide
  • lutetium Lu 177 dotatate
  • Octreotide